These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31758536)

  • 1. Stimulatory and Inhibitory Co-signals in Autoimmunity.
    Okazaki T; Okazaki IM
    Adv Exp Med Biol; 2019; 1189():213-232. PubMed ID: 31758536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
    Fife BT; Bluestone JA
    Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges and opportunities in targeting the CD28/CTLA-4 pathway in transplantation and autoimmunity.
    Crepeau RL; Ford ML
    Expert Opin Biol Ther; 2017 Aug; 17(8):1001-1012. PubMed ID: 28525959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The B7:CD28 family and friends: Unraveling coinhibitory interactions.
    Burke KP; Chaudhri A; Freeman GJ; Sharpe AH
    Immunity; 2024 Feb; 57(2):223-244. PubMed ID: 38354702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types.
    Oyewole-Said D; Konduri V; Vazquez-Perez J; Weldon SA; Levitt JM; Decker WK
    Front Immunol; 2020; 11():608024. PubMed ID: 33384695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New regulatory co-receptors: inducible co-stimulator and PD-1.
    Okazaki T; Iwai Y; Honjo T
    Curr Opin Immunol; 2002 Dec; 14(6):779-82. PubMed ID: 12413529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CD28-B7 Family of Co-signaling Molecules.
    Nagai S; Azuma M
    Adv Exp Med Biol; 2019; 1189():25-51. PubMed ID: 31758530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coinhibitory molecules in autoimmune diseases.
    Watanabe N; Nakajima H
    Clin Dev Immunol; 2012; 2012():269756. PubMed ID: 22997525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Not Available].
    Senant M; Giusti D; Weiss L; Dragon-Durey MA
    Bull Cancer; 2016 Nov; 103 Suppl 1():S175-S185. PubMed ID: 28057182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting T cell costimulation in autoimmune disease.
    Stuart RW; Racke MK
    Expert Opin Ther Targets; 2002 Jun; 6(3):275-89. PubMed ID: 12223069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.
    Wang SD; Li HY; Li BH; Xie T; Zhu T; Sun LL; Ren HY; Ye ZM
    Int Immunopharmacol; 2016 Sep; 38():81-9. PubMed ID: 27258185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A transendocytosis perspective on the CD28/CTLA-4 pathway.
    Soskic B; Qureshi OS; Hou T; Sansom DM
    Adv Immunol; 2014; 124():95-136. PubMed ID: 25175774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
    Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
    Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTLA-4: From mechanism to autoimmune therapy.
    Hosseini A; Gharibi T; Marofi F; Babaloo Z; Baradaran B
    Int Immunopharmacol; 2020 Mar; 80():106221. PubMed ID: 32007707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis.
    Cho H; Kang H; Lee HH; Kim CW
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28703774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cells of staphylococcal enterotoxin B-tolerized autoimmune MRL-lpr/lpr mice require co-stimulation through the B7-CD28/CTLA-4 pathway for activation and can be reanergized in vivo by stimulation of the T cell receptor in the absence of this co-stimulatory signal.
    Zhou T; Weaver C; Linsley PS; Mountz JD
    Eur J Immunol; 1994 May; 24(5):1019-25. PubMed ID: 7514125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CTLA-4 and T cell activation.
    Oosterwegel MA; Greenwald RJ; Mandelbrot DA; Lorsbach RB; Sharpe AH
    Curr Opin Immunol; 1999 Jun; 11(3):294-300. PubMed ID: 10375557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of CTLA-4-Ig in tolerance induction.
    Alegre ML; Fallarino F
    Curr Pharm Des; 2006; 12(2):149-60. PubMed ID: 16454732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.